For Immediate Release

August 19, 2022

Media Contact

AABB
Jay Lewis
+1.301.215.6593
jlewis@aabb.org

AABB Introduces New Biotherapies Credentialing Program

BETHESDA, Md. – The Association for the Advancement of Blood & Biotherapies (AABB) recently introduced the AABB Certified Advanced Biotherapies Professional (CABP) credentialing program. This is the first and only certification for biotherapies professionals.

Becoming a CABP is a mark of distinction, establishing that qualified professionals have demonstrated – through a certification exam – that they have the necessary knowledge to credibly practice in the field of biotherapies.

“This certification benefits the entire biotherapies field by establishing minimum standards of competence, identifying qualified and proficient professionals, and advancing knowledge, safety and quality,” said Debra BenAvram, CEO of AABB. “Certifying provides an opportunity

for high-performing biotherapies professionals to demonstrate their commitment and competence, distinguish themselves from their peers, and position themselves for career advancement.”

The CABP examination is open to all advanced biotherapies professionals including fellows, laboratorians, medical directors, nurses, pharmacists, quality and regulatory specialists, and researchers. The exam domains address the full breadth of topics within the field of biotherapies: Biotherapies in the Patient Care Ecosystem, Biotherapies Science and Ethics, Operations and Equipment, Biotherapies Development Lifecycle, Manufacturing, Quality Systems, and Regulatory Environment.

Detailed information is available at www.aabb.org/cabp.

About AABB

AABB (Association for the Advancement of Blood & Biotherapies) is an international, not-for-profit organization representing individuals and institutions involved in the fields of transfusion medicine and biotherapies. The Association works collaboratively to advance the field by developing and delivering standards, accreditation, and education programs. AABB is dedicated to its mission of improving lives by making transfusion medicine and biotherapies safe, available, and effective worldwide. For more information, visit www.aabb.org.